ReviewNature reviews. Clinical oncology2015
Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?
Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-pharmacological interventions and quality of life in female survivors of hormone receptor-positive breast cancer receiving adjuvant endocrine therapy: A systematic review.Anales del sistema sanitario de Navarra · 2026Pooled it
- Cancer therapy-related cognitive impairment, part 1: an integrative clinical-mechanistic framework from phenotypes to convergent neurobiological pathways.Pharmacological reports : PR · 2026Review
- Women's midlife: the front line of Alzheimer prevention.The Journal of clinical investigation · 2026Review
- Selective oestrogen receptor modulators and Alzheimer´s disease: a real-world pharmacovigilance study.European journal of clinical pharmacology · 2026Article
- Effects of tamoxifen on cognitive function in patients with primary breast cancer.British journal of cancer · 2025Article
- Cognitive functioning in older transgender individuals receiving long-term gender-affirming hormone therapy.International journal of transgender health · 2025Article
- Comprehensive analysis of the relationship between RNA modification writers and immune microenvironment in head and neck squamous cell carcinoma.BMC immunology · 2024Article
- Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer.JNCI cancer spectrum · 2023Article
- Review
- Content validity evidence of the Brazilian version of the Cognitive Symptom Checklist-Work-21.Revista brasileira de enfermagem · 2023Article
- Behavioral and transcriptomic effects of the cancer treatment tamoxifen in mice.Frontiers in neuroscience · 2023Article
- A novel oncogenic enhancer of estrogen receptor-positive breast cancer.Molecular therapy. Nucleic acids · 2022Article
- Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy.Breast cancer research and treatment · 2022Observational
- Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.Frontiers in aging neuroscience · 2022Review
- Association of APOE4 genotype and treatment with cognitive outcomes in breast cancer survivors over time.NPJ breast cancer · 2021Article
- Measuring decline in white matter integrity after systemic treatment for breast cancer: omitting skeletonization enhances sensitivity.Brain imaging and behavior · 2021Article
- Neuropsychiatric effects of tamoxifen: Challenges and opportunities.Frontiers in neuroendocrinology · 2020Review
- Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.Cancer science · 2020Article
- Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of breast cancer survivors is gradually increasing and a subset of these patients experience long-term adverse effects of adjuvant systemic therapy, including cognitive decline. Surprisingly, relatively little is known about the long-term adverse effects of endocrine treatment on cognition. As 75% of all patients with breast cancer are eligible to receive hormonal treatment, understanding the potential neurocognitive adverse effects of such therapy is of utmost importance. Concerns about adverse cognitive effects of adjuvant endocrine therapy are timely, as recently updated guidelines recommend increasing the length of such therapy from 5 years to 10 years for a subset of patients. The decline of cognitive functions can have a detrimental impact on quality of life and might interfere with independent living. This Review discusses the tissue-selective side effects of endocrine therapies and specifically their impact on cognitive function, on the basis of clinical data; the neurobiological effects of endocrine therapies as observed in preclinical models are also discussed. We highlight the critical issues that need to be addressed in future preclinical and clinical studies in order to best assess the cognitive effects of endocrine treatment in patients with breast cancer.
Indexed as
Identifiers
26196252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.